Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Stock Performance

EVGN stock opened at $1.15 on Thursday. The firm has a market cap of $6.14 million, a P/E ratio of -0.26 and a beta of 1.28. The firm’s fifty day moving average is $1.43 and its 200 day moving average is $1.79. Evogene has a 52 week low of $1.17 and a 52 week high of $9.00.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The firm had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. During the same period last year, the firm earned ($1.30) earnings per share.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Jane Street Group LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.40% of Evogene at the end of the most recent reporting period. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.